4th Annual Highly Potent Active Pharmaceutical Ingredients conference 2020

SMi Group 11 - 12 May 2020, London, UK.
SMi is delighted to announce its 4th Annual Highly Potent Active Pharmaceutical Ingredients conference 2020 (HPAPI 2020) coming to London on the 11th - 12th May 2020. The conference focuses on the growing landscape driven by the demand for highly potent drugs in oncology, diabetes and autoimmune disease treatment.

HPAPI 2020 will address the biggest challenges the industry is facing with regards to determining toxicology limits, assessing hazards, implementing risk procures, translating risk assessment into facility engineering, preventing and dealing with cross-contamination and adhering to GMP regulatory guidelines.

Attend the conference and join our networking platform for industry professionals to provide you with the expertise to overcome the challenges of the HPAPI industry.

Network and learn from leading professionals such as:

Chair for 2020

  • Justin Mason-Home, Director, HPAPI Project Services Limited

Key speakers include

  • Pascal Michoux, Vice President, Global EHS Teva api & Biologics, teva API Italy
  • William Hawkins, Manager Occupation Toxicology, GsK
  • Brian Edwards, Chair, Pharmaceutical Human Factors Group, CIeHf
  • Thomas Adam, Head of GQA Chemical APIs, Bayer AG
  • Ildikó Ziegler, QA Manager, Gedeon Richter
  • Francois D’Hooge, ADC Project Manager, Gamamabs Pharma
  • Andreas Schreiner, Head of Validation, Novartis

Featured highlights

  • Explore HPAPI manufacturing with 8 big pharma from both the toxic substance and the employees’ perspective
  • Gain better understanding of human factors and ergonomics aspects and their role in improving production performance with the
  • Chartered Institute of Ergonomics and Human Factors
  • Deep dive into the oncology market and ADC production, the main driver of the HPAPI industry
  • Learn what it takes to create a safety company culture and how to better train your employees on risk perception

For further information and to register, please visit:
http://www.highlypotentapi.com/WPNEWs

About SMi Group

Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world's most forward-thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network.

Most Popular Now

SK bioscience and GSK start Phase 3 trial of adjuv…

SK bioscience (SK) and GlaxoSmithKline plc (GSK) today announced the initiation of a Phase 3 clinical study of SK's COVID-19 vaccine candidate, GBP510, in combination wit...

No serious health effects linked to mRNA COVID-19 …

Federal and Kaiser Permanente researchers combing the health records of 6.2 million patients found no serious health effects that could be linked to the 2 mRNA COVID-19 v...

Blood vessels produce growth factor that promotes …

Blood vessels supply tumors with nutrients and, on the other hand, enable cancer cells to spread throughout the body. The settlement of circulating tumor cells in a dista...

First-in-human clinical trial for a vaccine to tre…

The first patients have been enrolled in a phase 1 randomized placebo-controlled clinical trial to study a therapeutic vaccine for opioid use disorder developed by resear...

Sandoz strengthens pipeline by entering into agree…

Sandoz, a Novartis division, today announced that it has entered into a commercialization agreement with Bio-Thera Solutions, Ltd. for biosimilar bevacizumab (BAT1706). B...

Pfizer and BioNTech submit a variation to EMA with…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced that they submitted a variation to the European Medicines Agency (EMA) requesting to update the Condition...

A drug costing less than €2 a day helps in the tre…

Metoprolol, a drug widely used to treat cardiovascular disease, is beneficial when administered to COVID-19patients. This is the finding of a study by investigators at th...

Rheumatoid arthritis treated with implanted cells …

With a goal of developing rheumatoid arthritis therapies with minimal side effects, researchers at Washington University School of Medicine in St. Louis have genetically ...

NIH scientists build a cellular blueprint of multi…

Chronic lesions with inflamed rims, or "smoldering" plaques, in the brains of people with multiple sclerosis (MS) have been linked to more aggressive and disabling forms ...

Scientific evidence to date on COVID-19 vaccine ef…

An expert review by an international group of scientists, including some at the WHO and FDA, concludes that, even for the delta variant, vaccine efficacy against severe C...

How a plant virus could protect and save your lung…

Using a virus that grows in black-eyed pea plants, nanoengineers at the University of California San Diego developed a new treatment that could keep metastatic cancers at...

COVID-19 nasal vaccine candidate effective at prev…

Breathe in, breathe out. That’s how easy it is for SARS-CoV-2, the virus that causes COVID-19, to enter your nose. And though remarkable progress has been made in develop...